Stevanato Group (STVN) Stock Overview
Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for STVN from our risk checks.
STVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Stevanato Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.98 |
| 52 Week High | US$28.00 |
| 52 Week Low | US$17.12 |
| Beta | 0.57 |
| 1 Month Change | 7.58% |
| 3 Month Change | 5.91% |
| 1 Year Change | 38.71% |
| 3 Year Change | 53.64% |
| 5 Year Change | n/a |
| Change since IPO | 32.08% |
Recent News & Updates
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Sep 22
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
Aug 08Recent updates
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Sep 22Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
Aug 08Stevanato: Expansion In Italy And The U.S. Will Pave The Way
Jul 22Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt
Jun 23A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)
May 19Shareholders Should Be Pleased With Stevanato Group S.p.A.'s (NYSE:STVN) Price
Mar 26Stevanato: Ramping Syringe Demand, Buy Confirmed
Mar 09Is Stevanato Group (NYSE:STVN) A Risky Investment?
Feb 27Calculating The Fair Value Of Stevanato Group S.p.A. (NYSE:STVN)
Feb 01Stevanato Group S.p.A. (NYSE:STVN) Not Lagging Market On Growth Or Pricing
Dec 09
Engineering Optimization And Capacity Expansion To Unlock Growth Opportunities
Optimizing the Engineering segment and strategic shifts towards ready-to-use systems are expected to drive cost savings, improve margins, and boost productivity.Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Nov 13Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think
Nov 12Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models
Nov 08We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt
Oct 23Stevanato: Destock Pressures, Long-Term Upside
May 29Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Mar 12Stevanato: Guidance Reiterated And Supportive Revenue Growth
Nov 22Stevanato: Secular Tailwinds In Biologics Support Downstream Demand
Sep 15Stevanato Group: Undeniable Quality, But Lacking Upside
Jun 14Stevanato Group and Transcoject to provide pre-fillable syringe polymer options for pharma
Jan 24Shareholder Returns
| STVN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.9% | 14.9% | 0.9% |
| 1Y | 38.7% | -11.7% | 18.4% |
Return vs Industry: STVN exceeded the US Life Sciences industry which returned -11.7% over the past year.
Return vs Market: STVN exceeded the US Market which returned 18.4% over the past year.
Price Volatility
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: STVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STVN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,521 | Franco Stevanato | www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.
Stevanato Group S.p.A. Fundamentals Summary
| STVN fundamental statistics | |
|---|---|
| Market cap | US$7.09b |
| Earnings (TTM) | US$157.71m |
| Revenue (TTM) | US$1.34b |
Is STVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STVN income statement (TTM) | |
|---|---|
| Revenue | €1.15b |
| Cost of Revenue | €820.71m |
| Gross Profit | €324.39m |
| Other Expenses | €189.83m |
| Earnings | €134.56m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 28.33% |
| Net Profit Margin | 11.75% |
| Debt/Equity Ratio | 28.8% |
How did STVN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 08:39 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stevanato Group S.p.A. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Hugo Solvet | BNP Paribas Exane |
| Curtis Moiles | BNP Paribas Exane |